By Daniella Parra
Jeito Capital said it led a $65 million Series A funding round in ReproNovo, a biotech company focused on reproductive medicine and women’s health/.
ReproNovo is addressing male and female infertility and uterine health advancing in RPN-001, an oral treatment for male infertility linked to low testosterone and RPN-002, a first-in-class oral treatment for adenomyosis and improving outcomes in assisted reproductive technologies.
“As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients,” Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital, said.
